Mithra Pharmaceuticals S.A. Logo

Mithra Pharmaceuticals S.A.

Biotech firm developing pharma for women's health: contraception, fertility, and menopause.

MITRA | BR

Overview

Corporate Details

ISIN(s):
BE0974283153 (+1 more)
LEI:
5493002FDD273HTEKK14
Country:
Belgium
Address:
Rue Saint-Georges 5, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mithra Pharmaceuticals S.A. is a biotechnology company dedicated to women's health. The company specializes in the development, manufacturing, and commercialization of proprietary and over-the-counter pharmaceutical products. Its core focus areas include contraception, fertility, and menopause. Mithra's mission is to transform the women's health sector by providing innovative new choices that aim to improve the overall quality of life for women.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_EN-FS (003) (002)-PDF.pdf
English 179.8 KB
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_FR-FS-PDF.pdf
French 126.7 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_EN.…
English 181.9 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_FR.…
French 128.7 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~1.PDF
English 153.0 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~2.PDF
French 158.7 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_EN.…
English 139.6 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_FR.…
French 143.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_EN.pdf
English 124.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_FR.pdf
French 126.5 KB
2024-05-03 17:30
M&A Activity
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
English 142.7 KB
2024-05-03 17:30
Capital/Financing Update
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
French 145.9 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_VOTING-BY-MAIL-FORM_AGO-MAY-2024_EN.pdf
English 141.0 KB
2024-04-30 10:30
Pre-Annual General Meeting Information
2024-04-30_MITHRA_AGENDA_AGO-MAY-2024_FR.pdf
French 143.1 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_PROXY-FORM_AGO-MAY-2024_EN.pdf
English 145.2 KB

Automate Your Workflow. Get a real-time feed of all Mithra Pharmaceuticals S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mithra Pharmaceuticals S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mithra Pharmaceuticals S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 NOSHAQ SA Board Other 172,574 617,814.92 EUR
2022-11-17 NOSHAQ SA Board Other 172,574 1,052,701.40 EUR
2022-07-18 NOSHAQ SA Board Other 156,250 1,006,250.00 EUR
2022-05-13 NOSHAQ SA Board Other 156,250 1,239,062.50 EUR
2022-04-13 Gordenne Valérie Other Sell 8,500 87,380.00 EUR
2022-03-29 Fornieri Francesco Board Sell 100,000 1,312,000.00 EUR
2022-03-25 Fornieri Francesco Board Sell 35,893 486,530.57 EUR
2022-03-24 Fornieri Francesco Board Sell 15,657 219,536.19 EUR
2022-03-24 Fornieri Francesco Board Sell 2,818 39,452.00 EUR
2022-03-23 Fornieri Francesco Board Sell 12,525 178,230.75 EUR

Peer Companies

Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN

Talk to a Data Expert

Have a question? We'll get back to you promptly.